


10/019,993

-2-

5661-01-SMH

**Amendments to the Claims:**

1. (Currently Amended) A compound of formula I



wherein :


$\text{R}^1$  is hydrogen,  $\text{C}_1\text{-C}_4$  alkyl, or  $\text{C}_2\text{-C}_4$  alkenyl;

$\text{R}^2$  and  $\text{R}^3$  independently are hydrogen,  $\text{C}_1\text{-C}_4$  alkyl, phenyl or benzyl, or taken together with the nitrogen to which they are attached complete a ring having from 4 to 7 ring atoms, one optionally being oxygen;


$\text{X}$  is  $(\text{CH}_2)_n$ ,  $\text{CHMe}-(\text{CH}_2)_{n-1}$  or  $(\text{CH}_2)_{n-1}\text{-CHMe}$ ,

$n$  is 1, 2 or 3;

$\text{R}^4$  is an aromatic or heteroaromatic group selected from



wherein  $\text{R}^5$  is hydrogen, halogen,  $\text{C}_1\text{-C}_4$  alkyl, nitro,  $\text{N}_3$  or  $\text{CF}_3$  and  $\text{R}^6$  is hydrogen,  $\text{C}_{1-4}$  alkyl, -



10/019,993

-3-


5661-01-SMH

and the pharmaceutically acceptable salts thereof,

with the proviso that in formula I:

when  $R^1$  is H,  $(X)_n$  is  $(CH_2)_2$  and  $R^2$  and  $R^3$  are both ethyl,  $R^4$  is not benzyl, 4-methylbenzyl, 4-chlorobenzyl, 2-chlorobenzyl, 4-bromobenzyl, 3-ethylbenzyl, 4-isopropylbenzyl, 4-n-propylbenzyl, 3-n-butylbenzyl, 2-t-butylbenzyl, 4-s-butylbenzyl or 2-bromobenzyl;  
when  $R^1$  is H,  $(X)_n$  is  $CH_2$  and  $R^4$  is benzyl,  $NR^2R^3$  is not  $NHCH_2Ph$ , N-piperidinyl,  $NH-t$ -butyl, N-morpholinyl, N-pyrrolidinyl, N-azepinyl,  $N(CH_3)_2$  or  $N(CH_2CH_3)_2$ ; and  
when  $R^1$  is n-butyl,  $(X)_n$  is  $(CH_2)_2$  and  $R^4$  is benzyl,  $NR^2R^3$  is not  $NHCH_2Ph$ .

2. (Original) A compound according to claim 1 wherein  $R^1$  is  $C_1$ - $C_4$  alkyl.
3. (Original) A compound according to Claim 2 wherein  $R^2$  and  $R^3$  independently are  $C_1$ - $C_4$  alkyl.
4. (Original) A compound according to Claim 3 wherein n is 2 or 3.
5. (Original) A compound according to Claim 4 wherein  $R^4$  is selected from




10/019,993

-4-


5661-01-SMH

6. (Original) A compound according to Claim 4 wherein R<sup>4</sup> is selected from




Claims 7- 11 (Cancelled).

12. (Original) A compound according to Claim 4 wherein R<sup>4</sup> is selected from



13. (Cancelled)

14. (Original) A compound according to Claim 4 wherein R<sup>4</sup> is selected from



10/019,993

-5-

5661-01-SMH

15. (Cancelled).
16. (Original) N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-chloronaphthalene.
17. (Original) N-Propionyl, N-(2-Diethylaminoethyl)-4-amino-9-fluorenone.
18. (Original) N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-bromonaphthalene.
19. (Cancelled).
20. (Currently Amended) N-Propionyl, N-(3-diethylamino-2-propyl)-1-amino-4-chloronaphthalene.
21. (Original) N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-azidonaphthalene.
22. (Original) N-Acryloyl, N-(2-diethylaminoethyl)-1-amino-4-chloronaphthalene.
23. (Original) N-Propionyl, N-(2-Diethylaminoethyl)-(1-amino-4-nitronaphthalene).
24. (Cancelled).
25. (Cancelled).
26. (Cancelled).
27. (Currently Amended) A method according to claim 32 ~~26~~ wherein the CNS disorder is selected from pain, depression, anxiety, or schizophrenia.
28. (Currently Amended) A method according to Claim 32 ~~26~~ wherein the CNS disorder is selected from Huntington's disease, Alzheimer's disease or amyotrophic lateral sclerosis.

10/019,993

-6-

5661-01-SMH

29. (Currently Amended) A compound according to Claim 5 which is selected from

N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-chloronaphthalene;  
N-Propionyl, N-(2-Diethylaminoethyl)-4-amino-9-fluorenone;  
N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-bromonaphthalene;  
N-Propionyl, N-(N-Morpholino)-1-amino-4-chloronaphthalene;  
N-Propionyl, N-(3-diethylamino-2-propyl)-1-amino-4-chloronaphthalene;  
N-Propionyl, N-(2-Diethylaminoethyl)-1-4-azidonaphthalene;  
N-Propionyl, N-(2-Diethylaminoethyl)-3-chlorobenzyl-amine;  
N-Propionyl, N-(2-Diethylaminoethyl)-3-bromobenzyl-amine;  
N-Propionyl, N-(2-Piperidylethyl)-1-amino-4-chloronaphthalene;  
N-Propionyl, N-(2-(3-dimethylamino-propyl))-1-amino-4-chloronaphthalene;  
N-Propionyl, N-(2-Dimethylaminoethyl)-1-amino-4-chloronaphthalene;  
N-Propionyl, N-(2-(N-benzyl)-aminoethyl)-1-aminonaphthalene;  
N-(2-Diethylamino-ethyl)-N-(7-methyl-quinolin-4-yl)-propionamide;  
N-Acryloyl, N-(2-diethylaminoethyl)-1-amino-4-chloronaphthalene; and  
N-Propionyl, N-(2-Diethylaminoethyl)-(1-amino-4-nitronaphthalene).

30. (Previously Presented) A compound according to Claim 1 which is a pharmaceutically acceptable salt.

31. (Previously Presented) A pharmaceutical formulation comprising a compound of Claim 1 together with a pharmaceutically acceptable diluent, carrier or excipient therefor.


32. (Previously Presented) A method for treating a CNS disorder in a mammal in need of treatment comprising administering a CNS effective amount of a compound of Claim 1.

33. (New) A method for treating a CNS disorder in a mammal in need of treatment comprising administering a CNS effective amount of a compound

10/019,993

-7-



5661-01-SMH



wherein :

R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>2</sub>-C<sub>4</sub> alkenyl;R<sup>2</sup> and R<sup>3</sup> independently are hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl or benzyl;X is (CH<sub>2</sub>)<sub>n</sub>, CHMe-(CH<sub>2</sub>)<sub>n-1</sub> or (CH<sub>2</sub>)<sub>n-1</sub>-CHMe,

n is 1, 2 or 3;

R<sup>4</sup> is an aromatic or heteroaromatic group selected fromwherein R<sup>5</sup> is hydrogen, halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, nitro, N<sub>3</sub> or CF<sub>3</sub> and R<sup>6</sup> is hydrogen, C<sub>1-4</sub> alkyl, -

and the pharmaceutically acceptable salts thereof.